Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Retrospective study of phentermine and topiramate in a United States claims database

Next Previous
Search
Trial Profile

Retrospective study of phentermine and topiramate in a United States claims database

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Mar 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 26 Feb 2019 According to a VIVUS media release, data from this study were published in The Journal of Clinical Endocrinology & Metabolism.
  • 14 Jan 2019 According to a VIVUS media release, the company plans to include the findings from this study in the ongoing discussions with the U.S. Food and Drug Administration related to the requested label modification for Qsymia. The requested modification would allow for the safe and effective short-term use of Qsymia and could potentially reduce or modify the need for a cardiovascular outcomes study.
  • 14 Jan 2019 According to a VIVUS media release, new findings from this study will be published in the February 1, 2019 issue of The Journal of Clinical Endocrinology & Metabolism and are currently available online.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top